New Step by Step Map For Fluoxetine
Kantarjian et al53 assessed the efficacy and security of dasatinib, as as opposed with imatinib, for the initial-line treatment of CML-CP. Five hundred and nineteen clients with newly diagnosed CML-CP have been randomly assigned to receive dasatinib at a dose of one hundred mg once everyday (259 clients) or imatinib in a dose of 400 mg after every